Skye Depreciation vs Begin Period Cash Flow Analysis
SKYE Stock | USD 3.85 0.56 12.70% |
Skye Bioscience, financial indicator trend analysis is much more than just breaking down Skye Bioscience, Common prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Skye Bioscience, Common is a good investment. Please check the relationship between Skye Bioscience, Depreciation and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Depreciation vs Begin Period Cash Flow
Depreciation vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Skye Bioscience, Common Depreciation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Skye Bioscience,'s Depreciation and Begin Period Cash Flow is 0.55. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Skye Bioscience, Common, assuming nothing else is changed. The correlation between historical values of Skye Bioscience,'s Depreciation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Skye Bioscience, Common are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Depreciation i.e., Skye Bioscience,'s Depreciation and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.55 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Depreciation
Depreciation indicates how much of Skye Bioscience, Common value has been used up. For tax purposes Skye Bioscience, can deduct the cost of the tangible assets it purchases as business expenses. However, Skye Bioscience, Common must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from Skye Bioscience,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Skye Bioscience, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At present, Skye Bioscience,'s Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Tax Provision | 2.1K | 6.7K | 3.6K | 3.0K | Income Tax Expense | 2.1K | 6.7K | 3.6K | 2.8K |
Skye Bioscience, fundamental ratios Correlations
Click cells to compare fundamentals
Skye Bioscience, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Skye Bioscience, fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Current Liab | 410.6K | 341.8K | 954.9K | 7.6M | 8.3M | 4.7M | |
Total Current Liabilities | 970.8K | 787.2K | 3.9M | 12.1M | 13.9M | 14.6M | |
Net Tangible Assets | (15.6M) | 548.1K | 450.8K | 5.9M | 6.7M | 7.1M | |
Retained Earnings | (32.2M) | (38.7M) | (47.3M) | (66.7M) | (104.4M) | (99.2M) | |
Accounts Payable | 129.8K | 381.4K | 900.0K | 1.8M | 1.2M | 653.5K | |
Other Current Assets | 12.1K | 195.0K | 629.1K | 412.0K | 11.0M | 11.5M | |
Total Current Assets | 2.0M | 2.7M | 9.6M | 8.9M | 11.7M | 12.2M | |
Common Stock | 182.9K | 288.1K | 476.1K | 913.5K | 12.3K | 11.7K | |
Property Plant Equipment | 3.4K | 2.0K | 7.3K | 234.7K | 269.9K | 283.4K | |
Total Assets | 2.0M | 2.7M | 9.9M | 9.1M | 11.9M | 6.0M | |
Total Stockholder Equity | 548.1K | 450.8K | 5.9M | (3.0M) | (2.1M) | (2.2M) | |
Cash | 1.8M | 2.5M | 9.0M | 1.2M | 1.3M | 1.2M | |
Non Current Assets Total | 2.0K | 7.3K | 243.0K | 167.4K | 289.6K | 304.0K | |
Common Stock Shares Outstanding | 182.9M | 1.0M | 1.7M | 493.7M | 7.0M | 6.7M | |
Non Current Liabilities Total | 477.9K | 1.4M | 78.7K | 1.7M | 171.2K | 162.7K | |
Total Liab | 1.4M | 2.2M | 4.0M | 12.1M | 14.1M | 8.3M | |
Net Invested Capital | 935.1K | 1.9M | 7.8M | (1.2M) | 2.2M | 2.4M | |
Net Working Capital | 1.0M | 1.9M | 5.7M | (3.2M) | (2.3M) | (2.4M) | |
Capital Stock | 182.9K | 288.1K | 476.1K | 913.5K | 12.3K | 11.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.